Search tickers (stock/ETF/mutual fund)...
  • Screener
  • Watchlist
  • Charts
  • Gurus
    • HBP.TO
    Helix Biopharma Corp
    Price:  
    0.97 
    CAD
    Volume:  
    500
    Canada | Biotechnology
    ValuationOverviewFinancialsForecastCompareHistorical PriceDividendsTransactionsPeople
    Valuation Summary
    Trading Multiples
    Peter Lynch Fair Value
    WACC
    Similar Stocks to HBP.TO
    MACK
    Merrimack Pharmaceuticals Inc
    NPHC
    Nutra Pharma Corp

    HBP.TO WACC - Weighted Average Cost of Capital

    The WACC of Helix Biopharma Corp (HBP.TO) is 8.4%.

    The Cost of Equity of Helix Biopharma Corp (HBP.TO) is 13.1%.
    The Cost of Debt of Helix Biopharma Corp (HBP.TO) is 5%.

    RangeSelected
    Cost of equity10.0% - 16.2%13.1%
    Tax rate25.9% - 26.5%26.2%
    Cost of debt5.0% - 5.0%5%
    WACC6.9% - 9.9%8.4%
    WACC

    HBP.TO WACC calculation

    CategoryLowHigh
    Long-term bond rate3.2%3.7%
    Equity market risk premium5.1%6.1%
    Adjusted beta1.351.97
    Additional risk adjustments0.0%0.5%
    Cost of equity10.0%16.2%
    Tax rate25.9%26.5%
    Debt/Equity ratio
    		11
    Cost of debt5.0%5.0%
    After-tax WACC6.9%9.9%
    Selected WACC8.4%

    HBP.TO's CAPM model and how its cost of Equity is calculated

    The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.

    This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.

    Here’s how we figure out the cost of equity for HBP.TO:

    cost_of_equity (13.10%) = risk_free_rate (3.45%) + equity_risk_premium (5.60%) * adjusted_beta (1.35) + risk_adjustments (0.25%)

    We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.